pyrotinib plus capecitabine

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Henan Cancer Hospital

Conditions

HER2 Positive Metastatic Breast CancerMetastatic Breast Cancer in the Brain

Phase 2

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer HospitalHER2 Positive Metastatic Breast Cancer

Start: 2018-11-20End: 2024-12-30Updated: 2023-09-25

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Not yet recruitingNCT06475443

Henan Cancer HospitalMetastatic Breast Cancer in the Brain

Start: 2024-06-15End: 2027-01-31Target: 32Updated: 2024-06-26

Phase 3

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.HER2 Positive Metastatic Breast Cancer

Start: 2017-05-03End: 2021-03-31Target: 240Updated: 2020-06-18

Related Papers

Cost-effectiveness analysis of the treatment pathway after trastuzumab treatment failure in patients with HER2-positive advanced breast cancer: a chinese health system perspective.

2026-05-18

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial.

2024-09-206 citations

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.

Journal of Clinical Oncology2023-06-011 citations

Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage

Current Oncology2022-08-238 citations

Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.

Journal of Clinical Oncology2022-06-012 citations

Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer

Cancer Research2022-02-1512 citations

Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.

2022-01-31121 citations

Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.

Journal of Clinical Oncology2021-05-2010 citations

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.

2021-02-11314 citations

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.

Journal of Clinical Oncology2020-05-2028 citations

Pyrotinib combined with capecitabine as first-line therapy for HER2-positive metastatic breast cancer: A pooled analysis of three randomized controlled trials.

Journal of Clinical Oncology2020-05-201 citations

Pyrotinib plus capecitabine for HER2-positive, trastuzumab-resistant metastatic breast cancer: A pooled analysis of three randomized controlled trials.

Journal of Clinical Oncology2020-05-20